Trk receptors are a family of three receptor tyrosine kinases (TrkA, TrkB, and TrkC), each of which can be activated by one or more of the four neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT3 and NT4).
The TRK receptor family is made up of the transmembrane proteins TrkA, TrkB, and TrkC. These receptor tyrosine kinases are expressed in human neuronal tissue and are crucial for the physiology of nervous system development and function. Neurotrophins (NTs) activate these receptor tyrosine kinases. For TrkA, BDGF, NT-4/5, and TrkB and TrkC, respectively, these latter substances are specific ligands known as NGF and NT-3.
When a ligand binds to a receptor, the receptors begin to oligomerize and certain tyrosine residues in the intracytoplasmic kinase domain become phosphorylated. As a result of this action, signal transduction pathways that promote proliferation, differentiation, and survival in both healthy and malignant neuronal cells are activated.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69602 | (3aR)-Selitrectinib ((3aR)-LOXO-195) | 1350884-56-8 | (3aR)-Selitrectinib ((3aR)-LOXO-195) is an isomer of Selitrectinib. |
|
V78306 | 1D228 | 1D228 is a c-Met/TRK inhibitor (antagonist) with anti-tumor activity. | |
|
V69587 | 2-Bromo-6-methoxynaphthalene | 5111-65-9 | 2-Bromo-6-methoxynaphthalene is an active intermediate in the production of anti-inflammatory agents such as Naproxen and Nabumetone via the Heck reaction. |
|
V69583 | Amitriptyline-d3 hydrochloride | 342611-00-1 | Amitriptyline-d3 HCl is the deuterated form of Amitriptyline ( HCl). |
|
V69600 | Amitriptyline-d6 hydrochloride (amitriptyline d6 hydrochloride) | 203645-63-0 | Amitriptyline-d6 ( HCl) is the deuterated form of Amitriptyline HCl. |
|
V0642 | ANA-12 | 219766-25-3 | ANA-12 (ANA12) is a novel, potent and selective TrkB inhibitor/antagonist with important biological activity. |
|
V69592 | Anizatrectinib (hTrkA-IN-1) | 1824664-89-2 | Anizatrectinib (hTrkA-IN-1) is a potent oral TrkA kinase inhibitor (antagonist) with IC50 of 1.3 nM, compound 2. |
|
V69590 | Bedinvetmab (ZTS-00508841) | 2171034-69-6 | Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) directed against nerve growth factor (NGF). |
|
V4146 | CH7057288 | 2095616-82-1 | CH7057288 is a novel, potent and selectiveinhibitor of TRK (tyrosine receptor kinase) with IC50 values of 1.1 nM, 7.8 nM and 5.1 nM for TRKA, TRKB, and TRKC respectively. |
|
V69581 | Cyclotraxin B | 1203586-72-4 | Cyclotraxin B is a cyclic peptide that is a potent and specific TrkB inhibitor (antagonist) without altering BDNF binding. |
|
V78959 | Cyclotraxin B TFA | Cyclotraxin B TFA is a cyclic peptide that is a potent and specific TrkB inhibitor (antagonist) without altering BDNF binding. | |
|
V69601 | ENT-C225 | 2919962-53-9 | ENT-C225 is a potent activator of the TrkB neurotrophin receptor. |
|
V0641 | GNF-5837 | 1033769-28-6 | GNF-5837 (GNF5837) is an orally bioavailable pan-TRK (TrkA, TrkB)inhibitor with potential antitumor activity. |
|
V69586 | GNF-8625 monopyridin-N-piperazine hydrochloride | 2412055-62-8 | GNF-8625 monopyridin-N-piperazine HCl (TRKi-2) is an inhibitor (blocker/antagonist) of TRK, information is from patent WO 2020038415 A1. |
|
V0640 | GW441756 | 504433-23-2 | GW441756 (GW-441756) is a novel, potent and selective inhibitor of TrkA (Tropomyosin-related kinase A) with potential anticancer activity. |
|
V2683 | Larotrectinib (LOXO-101; ARRY-470) | 1223403-58-4 | Larotrectinib (LOXO-101; LOXO101; ARRY470;ARRY-470; Vitrakvi)is an orally bioactive, highly selective, ATP competitive TRK inhibitor with potential anticancer activity. |
|
V2599 | Larotrectinib sulfate (LOXO-101; ARRY-470) | 1223405-08-0 | Larotrectinib sulfate (LOXO-101; ARRY-470; Vitrakvi), the suldate salt of Larotrectinib,is a potent, oral, selective, ATP competitive TRK inhibitor with IC50s in low nanomolar range (2 to 20 nM) for inhibition of all TRK family members in binding and cellular assays. |
|
V30834 | LM22B-10 | 342777-54-2 | LM22B-10 (LM22B10) is a novel, potent activator of TrkB/TrkC (Tropomyosin-receptor kinase) neurotrophin receptor, inducing TrkB, TrkC, AKT and ERK activation in vitro and in vivo. |
|
V69585 | LPM4870108 | 2803679-07-2 | LPM4870108 is a potent and orally bioactive pan-Trk (WT/MT) inhibitor (antagonist) with IC50s of 0.2 nM, 2.4 nM, 3.5 nM and 2.3 nM for TrkC, TrkA, TrkAG595R and TrkAG667C, respectively. |
|
V80204 | Multi-kinase-IN-6 | Multi-kinase-IN-6 (compound 10e) is a multi-kinase inhibitor that shows good enzyme inhibitory effect against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1 and CDK2. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
